Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study

NCT02103257 is registered in ClinicalTrials.gov with Betta Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT02103257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02103257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study
Lead sponsor
Betta Pharmaceuticals Co., Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
March 31, 2014
Completion date
September 30, 2017
Enrollment
192 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, egfr positive non-small cell lung cancer